Martin Godbout holds a B.Sc. in biochemistry (1979) and a Ph.D. in physiology and molecular endocrinology from Laval University. From 1985 to 1990, he received a postdoctoral fellowship from the Medical Research Council (MRC) of Canada and went to San Diego, California, where he was trained in Neuromolecular Biology, at The Scripps Research Institute.

In 1991, Dr. Godbout came back to Laval University as an Asssistant Professor at the Department of Psychiatry at the Faculty of Medicine. The same year, the Quebec Foundation for Mental Disorder awarded Dr. Godbout the Grand Prix Recherche for his previous works on Alzheimer’s disease. From December 1993 to April 1994, he was Assistant Managing Director responsible for biopharmaceutical industry relations at the Research Centre of Centre Hospitalier de l’Université Laval (CHUL). In 1994, l’Université Laval awarded Dr. Godbout of the “Prix Summa” from the Faculty of Science and Engineering, and the same year, he founded BioContact Québec, an international biopharmaceutical partnership symposium. Since August 2005, Dr. Godbout has been named Officer of the Order of Canada.

From May 1994 to May 1997, he was named President and General Manager of Société Innovatech Québec, a $60 million technology investment fund. From May 1, 1997, Dr. Godbout was the Senior Vice-President of BioCapital, a Canadian venture capital firm specializing in seed-to-mezzanine stage private financing of companies demonstrating strong potential in the healthcare and biotechnology sectors. From April 1, 2000 to October 2009, Dr. Godbout was the Founder, President & CEO of Genome Canada, a private, not-for-profit Corporation, dedicated to investing and implementing a national strategy in genomics and proteomics research in Canada.

In March 2006, Dr. Godbout was shortlisted by the editors of Nature Biotechnology, as one of twenty nominees who have made the most remarkable and influential contribution to biotech in the past ten years in the category “Biobusiness in the rest of the world”. Dr. Godbout is presently a member of the board of directors of several Canadian biopharmaceutical companies, foundations and scientific Canadian organizations such as Acasti Pharma, AmorChem, AngioChem, AsmaCure, MethylGene (chairman), Génome Québec (chairman), BioContact, BioQuébec FQRS, Montréal In Vivo et la Fondation de l’ataxie de Charlevoix. Dr. Godbout has been a member of the Board of the “Conseil de la Science et de la Technologie du Québec” from 1996 to 2004 and of the National Science and Engineering Research Council of Canada from 1999 to 2002. Dr. Godbout has authored or co-authored more than 60 publications and abstracts, and has been invited as speaker at numerous scientific and financial conferences.

Dr. Drutz is President & CEO of DARA BioSciences (Nasdaq:DARA) in Raleigh, North Carolina, and was formerly a General Partner with Pacific Rim Ventures Co., Ltd. (PRV), an international venture capital investment firm focused on life sciences with headquarters in Tokyo, Japan. While with PRV he cofounded Tranzyme Pharma (Nasdaq:TZYM), resigning prior to its IPO after 11 years as chairman. He is currently Chairman of Vaxin, Inc. a private vaccine development company in Birmingham, Alabama; and Chairman of Gentris Corporation, a private pharmacogenomics services company in Research Triangle Park, North Carolina. He is also an international advisor and reviewer for Genome Canada and a member of its Science and Industry Advisory Committee (SIAC). During his earlier career, Dr. Drutz was Professor of Medicine and Microbiology and Chief of the Division of Infectious Diseases, University of Texas Health Science Center in San Antonio, Texas. While in Texas, he founded and directed the Center for Cell Regulation under National Science Foundation funding. He was subsequently Vice President, Biological Sciences and Vice President, Clinical Investigation for Smith, Kline & French Laboratories in Philadelphia. In 1990, he was appointed Vice President Clinical Development and Director for Daiichi Pharmaceutical Corporation, in Fort Lee, New Jersey. Dr. Drutz also served as President, Chief Executive Officer and Director of two drug discovery and drug development companies, Sennes Drug Innovations, Inc. in Houston, Texas, and Inspire Pharmaceuticals, Inc., Durham in North Carolina. Dr. Drutz holds a B.A. and M.D. from the University of Louisville and received postdoctoral training at Vanderbilt University School of Medicine. He is a Fellow of the American College of Physicians and the Infectious Diseases Society of America.

Henry J. Fuchs, MD is currently Executive Vice President and Chief Medical Officer of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and is a seasoned biotech drug development executive. From 2005 to 2008, Dr. Fuchs was Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals (NASDAQ: ONXX), overseeing expanded development of the kinase inhibitor Nexavar and other key development programs. From 1996 to 2005, Dr. Fuchs served in multiple roles of increasing responsibility at Ardea Biosciences (NASDAQ: RDEA), first as Vice President, Clinical Affairs, then as President and Chief Operating Officer, and finally as Chief Executive Officer. From 1987 to 1996, Dr. Fuchs held various positions at Genentech where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin to treat metastatic breast cancer. Dr. Fuchs received an M.D. degree from George Washington University and a B.A. degree in biochemical sciences from Harvard University.

Mr. Grubsztajn was appointed President and Chief Executive Officer of the corporation in September 2010. He recently led the Company’s $34.5 million financing in April 2011. Prior to this, he led MethylGene’s business development activities since 2005 with responsibilities that included executing licensing opportunities, corporate partnerships, strategic alliances and research collaborations. Mr. Grubsztajn played a lead role in out-licensing deals that together have generated more than US$100 million in cash for the Company. He led MethylGene’s 2006 US$272M cancer co-development and profit-share deal with Pharmion Corporation (now Celgene Corporation) and a second research collaboration with Pharmion worth up to $100M for the development of inhibitors targeting sirtuins for cancer. In addition, he secured a $55M research partnership with Otsuka Pharmaceuticals for ocular diseases. Prior to joining MethylGene, Mr. Grubsztajn was employed at Caprion Pharmaceuticals (now Caprion Proteomics) where he was involved in numerous technology out-licensing and in-licensing deals with pharmaceutical and biotechnology companies, as well as academia and governments. Mr Grubsztajn is a member of the Licensing Executives Society and has presented at several workshops. He has been a board or committee member of the Maimonides Geriatric Centre Foundation since 2001. In 2008, Mr. Grubsztajn was granted the Certified Licensing Professional designation from the Licensing Executives Society. He received his MBA and Law degrees from McGill University.

Louis Lacasse has been President of GeneChem Management Inc. since 1997 and Managing Partner of AgeChem Financial Inc. since 2006. GeneChem and AgeChem are managing three life sciences venture capital funds which have invested in more than forty (40) companies in Canada, USA and Europe.

Prior to joining GeneChem, Mr Lacasse worked at the Caisse de dépôt et de placement du Québec, where he held several positions between 1987-1997, including vice-president of Sofinov, a private placement subsidiary of the Caisse which focussed on biotechnology, information technology and industrial technology. Before joining the Caisse, Mr Lacasse worked as a financial analyst with the National Bank of Canada, as account manager at the Bank of Montreal and as project manager at the Centre de Développement Technologique. He has also owned a small retail company.

Mr. Lacasse has been appointed to the boards of directors of many private and public companies. Among these we find BioChem Pharma Inc., Axcan Pharma Inc., Targeted Genetics Inc., MethylGene Inc. and Idun Pharmaceuticals Inc. He is currently on the board of two (2) publicly traded companies, Chairman of two audit committee and Chairman of one compensation committee.

He holds a bachelor’s degree in finance from the Ecole des Hautes Etudes Commerciales and an MBA from McGill University.

Mr. Mallet has worked in senior executive positions in the pharmaceutical industry in Canada, the United Kingdom, Switzerland, Sweden and Southeast Asia. He was President and Chief Executive Officer of Sandoz Canada Inc. (now Novartis AG) for seven years and is a past Chair of Canada’s Research-based Pharmaceutical Companies. He is currently also a director of Medgenesis Inc., a private Canadian pharmaceutical company, and has been a director of seven publicly-traded pharmaceutical companies. Mr. Mallet was a member of the Audit Committee and Chair of the Corporate Governance Committee for most of these companies.

Peggy Mulligan most recently served as Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals International, Inc (formerly Biovail Corporation), a multinational pharmaceutical company listed on both the New York Stock Exchange and Toronto Stock Exchange. During her tenure, she co-led the merger and subsequent integration with Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX). She is currently a member of the Board of Directors of Ontario Power Generation Inc. (“OPG”) and Chair of OPG’s Human Resources & Compensation Committee. From 2005 to 2007 Peggy served as Executive Vice President, Chief Financial Officer and Treasurer of Linamar Corporation (TSX:LNR). Previously Peggy spent eleven years in various roles at the Bank of Nova Scotia (NYSE/TSX: BNS), most recently as Executive Vice President, Systems & Operations. Before joining the Bank of Nova Scotia she was an Audit Partner with Price Waterhouse. In 2003 and 2004 Ms. Mulligan was named one of Canada’s Top 100 Most Powerful Women by the Women’s Executive Network.

She holds a B. Math (Honours) from the University of Waterloo and she is a Fellow of the Institute of Chartered Accountants (FCA) of Ontario.

Peter A. Thompson, M.D. is a biotechnology executive, investor and entrepreneur. He is a Venture Partner at Orbimed Advisors and the founder and Managing Director of Strategicon Partners, an investment and management services company. He co-founded Trubion Pharmaceuticals (NASDAQ: TRBN), and served as CEO and Chairman from its inception through its successful IPO and as a public company until his retirement in 2009. Dr. Thompson is the former Vice President & General Manager of Chiron Informatics at Chiron Corporation and held various executive positions in Becton Dickinson, including Vice President, Research and Technology Department prior to joining Chiron. Dr. Thompson is a co-founder of iMetrikus (now Numera), a clinical decision support company, where he served as CEO and Chairman. He serves as a Director on the Boards of Anthera Pharmaceuticals (NASDAQ: ANTH), Methylgene (TSX: MYG), Response Biomedical (TSX: RBM), Cleave Biosciences (Co-Founder), Principia Biosciences, & CoDa Therapeutics. Dr. Thompson is an Ernst & Young Entrepreneur of the Year awardee, an inventor on numerous patents, a board-certified internist and oncologist, and an Affiliate Professor of Neurosurgery at the University of Washington. He was on faculty at the National Cancer Institute trained in internal medicine training at Yale University and received his medical degree from Brown University.